Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone
Drug ID BADD_D02415
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder.[L7342] The injectable formulation is approved only for treatment of acute agitation in schizophrenia.[L7342]
Marketing Status approved
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D08687
MeSH ID C092292
PubChem ID 60854
TTD Drug ID D0R1JV
NDC Product Code 59762-1006; 72578-127; 0049-0354; 70771-1179; 70771-1181; 62135-993; 72578-125; 70771-1180; 72578-128; 57297-330; 59762-1012; 0049-0352; 62135-992; 0049-0358; 62135-991; 0049-0356; 70518-3376; 59762-1014; 62135-994; 70771-1182; 72578-126; 59762-1008
UNII 6UKA5VEJ6X
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C21H21ClN4OS
CAS Registry Number 146939-27-7
SMILES C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.0010.001795%
Akathisia17.01.02.002; 19.06.02.006--
Altered state of consciousness17.02.04.001; 19.07.01.0030.000612%-
Anxiety19.06.02.0020.003671%
Asthenia08.01.01.001---
Cardiac arrest02.03.04.0010.000408%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000408%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Completed suicide08.04.01.010; 19.12.01.0010.001020%-
Condition aggravated08.01.03.0040.001305%-
Cough22.02.03.0010.001387%
Delusion19.10.01.0010.001509%
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.001591%
Drug abuse19.07.06.0100.000408%-
Drug hypersensitivity10.01.01.0010.006648%-
Drug ineffective08.06.01.0060.006445%-
Drug interaction08.06.03.0010.000408%-
Dry mouth07.06.01.002--
Dyskinesia17.01.02.006--
Dysphagia07.01.06.0030.003671%
Dystonia17.01.03.0010.000612%-
Erythema23.03.06.001---
Hallucination19.10.04.003--
Hallucination, auditory19.10.04.0040.000408%-
Headache17.14.01.001--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperosmolar state14.05.01.005---
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene